Le Lézard9h
DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed publication entitled: ...
Medscape1d
Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug
Meloxicam is an enolcarboxamide with preferential COX-2 activity. Studies conducted on experimental models and human tissues indicate that meloxicam is a more potent inhibitor of COX-2 than COX-1 ...
Medscape6d
Optimal Aspirin Dose in Acute Coronary Syndromes
ACS: Acute coronary syndrome; CV: Cardiovascular; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; TIA: Transient ischemic attack.